27R Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.84 |
| 52 Week High | SEK 18.00 |
| 52 Week Low | SEK 7.59 |
| Beta | 1.34 |
| 11 Month Change | 29.46% |
| 3 Month Change | 32.15% |
| 1 Year Change | 114.68% |
| 33 Year Change | 247.76% |
| 5 Year Change | 76.46% |
| Change since IPO | 53.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 27R | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 8.0% | 4.2% | 1.1% |
| 1Y | 114.7% | -30.1% | 7.2% |
Return vs Industry: 27R exceeded the German Healthcare Services industry which returned -30.1% over the past year.
Return vs Market: 27R exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| 27R volatility | |
|---|---|
| 27R Average Weekly Movement | 7.3% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 27R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 27R's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 414 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
| 27R fundamental statistics | |
|---|---|
| Market cap | €615.66m |
| Earnings (TTM) | €15.19m |
| Revenue (TTM) | €101.42m |
40.5x
P/E Ratio6.1x
P/S RatioIs 27R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 27R income statement (TTM) | |
|---|---|
| Revenue | SEK 1.17b |
| Cost of Revenue | SEK 104.50m |
| Gross Profit | SEK 1.06b |
| Other Expenses | SEK 889.45m |
| Earnings | SEK 175.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 5.11 |
| Gross Margin | 91.06% |
| Net Profit Margin | 14.97% |
| Debt/Equity Ratio | 0% |
How did 27R perform over the long term?
See historical performance and comparison